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Abstract
Introduction: Adequate migration and differentiation of mesenchymal stem cells is essential for regeneration of large bone
defects. To achieve this, modern graft materials are becoming increasingly important. Among them, electrospun nanofiber
scaffolds are a promising approach, because of their high physical porosity and potential to mimic the extracellular matrix
(ECM).
Materials and Methods: The objective of the present study was to examine the impact of electrospun PLLA nanofiber
scaffolds on bone formation in vivo, using a critical size rat calvarial defect model. In addition we analyzed whether direct
incorporation of bone morphogenetic protein 2 (BMP-2) into nanofibers could enhance the osteoinductivity of the scaffolds.
Two critical size calvarial defects (5 mm) were created in the parietal bones of adult male Sprague-Dawley rats. Defects were
either (1) left unfilled, or treated with (2) bovine spongiosa, (3) PLLA scaffolds alone or (4) PLLA/BMP-2 scaffolds. Cranial CT-
scans were taken at fixed intervals in vivo. Specimens obtained after euthanasia were processed for histology,
histomorphometry and immunostaining (Osteocalcin, BMP-2 and Smad5).
Results: PLLA scaffolds were well colonized with cells after implantation, but only showed marginal ossification. PLLA/BMP-2
scaffolds showed much better bone regeneration and several ossification foci were observed throughout the defect. PLLA/
BMP-2 scaffolds also stimulated significantly faster bone regeneration during the first eight weeks compared to bovine
spongiosa. However, no significant differences between these two scaffolds could be observed after twelve weeks.
Expression of osteogenic marker proteins in PLLA/BMP-2 scaffolds continuously increased throughout the observation
period. After twelve weeks osteocalcin, BMP-2 and Smad5 were all significantly higher in the PLLA/BMP-2 group than in all
other groups.
Conclusion: Electrospun PLLA nanofibers facilitate colonization of bone defects, while their use in combination with BMP-2
also increases bone regeneration in vivo and thus combines osteoconductivity of the scaffold with the ability to maintain an
adequate osteogenic stimulus.
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Introduction
Surgical reconstruction of bone defects after injury or tumor
resection frequently requires the use of graft material. Autologous
bone grafts are a widely accepted standard of bone repair and
regeneration. Although there are many advantages to the use of
bone grafts, major drawbacks such as donor site morbidity and
restricted availability affect approximately 10% of patients in
clinical practice [1,2]. To overcome these drawbacks, artificial
bone grafts based on synthetic biomaterials such as metals,
polymers, porous ceramics, hydroxyapatite, collagen sponges or
hydrogels as well as several composites have been developed
recently [2–5]. Moreover, to engineer an effective bone graft
material, substances that are capable of triggering osteogenesis
such as growth factors have to be included [6]. Therefore a
scaffold should ideally function as a carrier for growth factors as
well as cells [7,8]. To support the latter, a scaffold must be three-
dimensional and porous, mimicking the extracellular matrix
(ECM) produced by healthy bone [9]. Considering this aspect,
scaffolds based on nanofibers offer great advantages [10,11] and
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compared to solid-walled architecture for the promotion of
osteoblast differentiation and biomineralization [12]. Nanofibers
can be obtained by several methods including self-assembly [13–
18], thermally induced liquid–liquid phase separation for the
formation of nanofibrous foam materials [19,20] or carbon
dioxide laser supersonic drawing [21] and electrospinning. Each
approach has unique advantages, lending itself to development as
a scaffolding system. Self-assembly for example can generate small
diameter nanofibers at the lowest end of the size-range of natural
extracellular matrix collagens. These scaffolds can support growth
and differentiation of MSC [18,22] in vitro as well as in vivo [17] and
may serve as a drug delivery system [23]. Phase separation, on the
other hand, generates nanofibers in the same range as natural
extracellular matrix collagens and allows for the design of
macropore structures. Electrospinning is one of the most pro-
mising methods of producing continuous fibers on a large scale.
Although the original method was first published in 1934 [24], the
technique was established in the early 1990s [25–27]. Simplified,
the process utilizes an electric field in order to charge a viscous
polymer solution. As a consequence electrostatic force draws the
fluid from the developing Taylor cone into a liquid jet. Due to
various interactions between electric field and the charged jet [26],
bending instability produces a spiral shaped trajectory. This
process is accompanied by solvent evaporation resulting in
formation of solid (nano-)fibers deposited on the collector electrode
as a non-woven mat. These fiber mats can be generated by
electrospinning from a large variety of polymers which have been
analyzed with respect to their possible use in tissue engineering
applications [3] using fibroblasts [28] tenocytes [29] neural stem
cells [30], MSC [31] or osteoblast like cell lines [32].
Whether or not a polymer can be electrospun into nanofibers
depends on a variety of factors including voltage, conductivity of
the solution, and entanglement density of the polymer, that in their
turn depend on its chemical nature and molecular weight, the
solvent and concentration used and on environmental conditions
[33,34]. Nevertheless to date more than 100 polymers have been
used to produce nanofibers [34]. With respect to tissue
engineering, among the polymers tested, biopolymers or biocom-
patible chemosynthetic polymers are of the greatest interest.
Among these, poly-L-lactic acid (PLLA) plays an important role
due to its biocompatibility, biodegradability and FDA approval
which allows its use in bone reconstructive surgery [35,36]. As
reported earlier, PLLA can easily be electrospun to form a 3D
non-woven network [37,38]. Furthermore, synthetic nanofibers
may exhibit certain properties similar to natural collagen fibers
and thus may serve as superior scaffolding compared to solid-
walled materials in promoting cell migration, differentiation and
subsequent biomineralization [12]. Earlier in vitro experiments
indicated that stem cells grow well on PLLA nanofiber scaffolds.
Nevertheless the presence of PLLA nanofibers resulted in a down-
regulation of genes associated with the osteoblast linage [39] which
can be overcome by combination of the nanofibers with collagen,
[39], RGD sequences [39,40] or BMP-2 [41]. BMP-2, which has
been shown to promote osteoblast activity [42] and has been
successfully applied in the reconstruction of bone defects in a
number of clinical studies [43–45], can be incorporated into
nanofiber scaffolds in a bioactive form by electrospinning.
Although there are some reports that the structural integrity of
BMP-2 [46] as well as its bioactivity [47] might be influenced by
electrospinning, bioactivity is retained in vitro [41].
Srouji et al. recently reported the use of a core-shell nanotube
system for the release of BMP-2 in vitro, also demonstrating a
possible in vivo application method [48]. Fu et al. used electrospun
PLGA/HAp nanofibers as a delivery system for BMP-2 and
observed good osteoinductive activity [47].
To our knowledge, no in vivo data are available analyzing the
effect of electrospun PLLA nanofiber scaffolds on bone formation
in a time dependent manner. Therefore the aims of this study were
to characterize the influence of PLLA nanofibers on bone
formation in vivo and to analyze whether BMP-2 enhances bone
healing when incorporated into PLLA nanofiber scaffolds by
electrospinning.
Materials and Methods
Fabrication of nanofibers
The preparation of PLLA nanofibers by electrospinning was
performed under aseptic conditions and has been previously
reported [31,39]. Briefly, a 4% (w/w) PLLA (Resomer L210,
Boehringer, Ingelheim, Germany) solution dissolved in dichloro-
methane was prepared at room temperature by stirring overnight
until a homogeneous solution was obtained. The spinning process
was performed at a flow rate of 14 mL/min with an applied voltage
of 20–30 kV and an electrode distance of 15 cm. In order to
incorporate BMP-2 into the nanofibers, 25 mg lyophilized rhBMP-
2 (Reliatech, Braunschweig, Germany) were dissolved in 125 mL
50 mM acetic acid and stabilized by the addition of 25 mL fetal
calf serum (FCS). This mixture was emulsified in 2.5 mL of a 4%
PLLA-dichloromethane solution. Samples of non-woven nanofi-
bers (approximately 1 mm in thickness) were collected on a sterile
aluminum plate with an area of 3600 mm
2 and trimmed to sizes of
25 mm
2 immediately before implantation. Based on the initial
conditions, BMP-2 concentration was about 6.94 ng/mL and thus
a single implant contained approximately 174 ng BMP-2. Further
characterization and physical properties of PLLA and PLLA/
BMP-2 scaffolds have previously been described in detail [31].
Animals
One hundred twenty five-month-old Sprague-Dawley rats
(Harlan Winkelmann, Borchen, Germany) were used in the
experiment. The animals were kept in individual plastic cages
(Macrolon Type III) in a room maintained at a constant
temperature of 22.1uC, with a 12 h light/dark cycle. They had
free access to drinking water and standard laboratory pellets
(LASQCdietH Rod16 Rad, LASVendi, Soest, Germany). All
experiments were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the NIH and approved by the local
Animal Ethics Committee Regierungspra ¨sidium Giessen under
reference number V 54 – 19 c 20-15 (1) MR 20/21- Nr. 18/2008.
Surgery
Animals were divided into four groups of 30 rats prior to
surgery. Bilateral full thickness critical size calvarial defects were
created in order to double the defect number and to spare the
sagittal sinus. Both defects were filled with one of the following
materials, dividing the population into four groups: (1) left unfilled
as a negative control, (2) press-fit bovine spongiosa implant as a
positive control (TutoboneH, Tutogen, Neunkirchen am Brand,
Germany), (3) PLLA nanofiber scaffolds or, (4) PLLA/BMP-2
nanofiber scaffolds. Ten animals per group were sacrificed after a
healing time of 4, 8, or 12 weeks.
Surgery was performed under general anesthesia by weight-
adjusted intraperitoneal injection of xylazine 2% (RompunH,
10 mg/kg body weight, Bayer Animal Health, Leverkusen,
Germany) and ketamine hydrochloride (Ketamin WDT, 100 mg/
kg body weight, WDT, Garbsen, Germany). The dorsal part of the
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(OcteniseptH, Schu ¨lke & Mayr, Norderstedt, Germany). An
approximately 20 mm long sagittal incision was made to include
skin and muscle. The periosteum was reflected and trimmed
exposing the parietal bones on both sides. Two bilateral 5 mm full
thickness critical size defects (CSD) were created using a trephine
bur (No. 229.040, Meisinger, Du ¨sseldorf, Germany) and carefully
positioned to leave sufficient normal bone surrounding the defects.
Constant irrigation with sterile physiological saline solution was
applied to prevent overheating of the bone margins. After
implantation of the appropriate material according to group, the
site was closed by suturing the overlying tissue and skin (Vicryl
rapide 3-0, Ethicon, Norderstedt, Germany). All operations were
carried out by an experienced surgeon (MDS). To prevent wound
infection each rat received a subcutaneous injection of 2 mL
ampicillin/sulbactam (A/S Kabi, 0.125 mL/kg body weight,
200,000 I.U./mL, Fresenius Kabi, Bad Homburg v. d. H.,
Germany).
Dual-source CCT
Radiographic evaluation was performed 4, 8 and 12 weeks after
surgery using cranial computed tomography (CCT) imaging
(Somatom Definition, Siemens Medical Systems, Erlangen,
Germany) with a resolution of 0.3 mm. All animals were
anesthetized as described above for the duration of the CT-scans.
Images were transferred to an image analysis workstation
(Leonardo, Siemens Medical Systems, Erlangen, Germany) for
evaluation. In order to analyze bone tissue repair, the radiological
density was measured by placing a region of interest (ROI) of the
same size as the original defect over each data set. Bone density
was measured in Hounsfield units (HU).
Harvesting of tissue and sectioning of test specimens
Animals were sacrificed by CO2-asphyxiation. Previously blood
was collected by cardiac puncture using a serum-gel tube and
screened for signs of inflammation (C-reactive protein) to evaluate
the animals’ postoperative systemic condition. The defect sites
were removed together with a small amount of surrounding bone,
skin and soft connective tissue. These samples were immediately
fixed in 4% buffered formalin for three days and then decalcified
in an EDTA-solution (OsteosoftH, Merck, Darmstadt, Germany)
over a period of 18 days. After trimming the bone specimens with
a precision saw they were dehydrated in graded alcohol solution
and cedar wood oil and embedded in paraffin. Sections were cut at
5 mm with a 40u stainless-steel blade on a rotation microtome
(RM2055, Leica Microsystems, Bensheim, Germany).
Histological and immunohistological staining
Histological staining was performed with Hematoxylin-Eosin
(HE) (Merck Chemicals, Darmstadt, Germany) and Masson
Goldner (MG) (Merck Chemicals) formulations according to
standard protocols.
For immunohistological staining the sections were rehydrated
and endogenous peroxidase activity quenched with a 4% hy-
drogen peroxide solution. They were blocked with normal horse
serum (Santa Cruz, Heidelberg, Germany) and incubated
overnight with a polyclonal IgG antibody against either osteocal-
cin, diluted 1:50 (FL-100, Santa Cruz), BMP-2, diluted 1:25 (N-14,
Santa Cruz) or Smad5, diluted 1:25 (D-20, Santa Cruz). Sections
were then incubated with a biotinylated secondary antibody (Santa
Cruz) diluted 1:50 for 30 min at room temperature. An avidin-
biotin-complex detection system coupled with DAB as a
chromogen (Santa Cruz) was used to visualize antibody binding
after 10 min incubation at room temperature. Finally all sections
were counterstained with Gill’s hematoxylin solution (Santa Cruz)
diluted 1:2 for 10 sec. Negative controls, incubated without
primary antibody, were treated in parallel with each of the
previously described staining procedures.
Histological, immunohistological and histomorphometric
analysis
All sections were histologically assessed following standard
Hematoxylin-Eosin staining prior to further investigation. Histo-
morphometric analysis was performed in Masson-Goldner tri-
chrome-stained sections at a primary magnification of 5-fold using
a digital microscope (DM5000, Leica Microsystems, Bensheim,
Germany) and QUIPS analysis software (Leica Microsystems).
Nine images per specimen were captured and assembled into a
montage displaying the whole defect. Formation of new bone was
calculated in relation to the whole defect area of each section and
expressed as a percentage. In the bovine spongiosa implants
(positive control) the histologically lighter trabecular areas of the
implants were disregarded, in order to quantify the formation of
new bone only. Cell counts were performed in five fields per
specimen, ranging from one end of the defect to the other, using a
primary magnification of 40-fold. Immunohistological evaluation
was carried out by selecting four representative regions of interest
(ROI) at 20-fold magnification - two regions in the marginal areas
of the defect and two in the center – connecting both defect
margins together.
Statistical analysis
Analysis of variance (ANOVA) was used to evaluate the
differences between experimental and control groups as well as
between different time points in a group. Data are given as means
6 standard deviation (SD). The level of significance was set at
p,0.05.
Results
Two animals were lost during surgery due to blood loss. Another
animal (PLLA/BMP-2 group) was lost postoperatively due to rapid
weight loss. All other animals (n=117) survived and the implant
sites healed well. Animals in groups receiving either bovine
spongiosa, PLLA or PLLA/BMP-2 showed firm fixation of the
implants on palpation. Groups receiving no implant macroscopi-
cally showed formation of a soft membrane of fibrous connective
tissue. Serum blood analysis of C-reactive protein (CRP) yielded no
signs of infection or inflammation. Levels in the negative control
group decreased from 44.5662.47 mg/L at week four to 19.856
1.68 mg/L after twelve weeks (p#0.001), in the bovine spongiosa
group from 39.5262.12 mg/L to 18.9462.15 mg/L (p#0.001), in
the PLLA group from 43.2168.67 mg/L to 19.3863.53 mg/L
(p#0.001) and in the PLLA/BMP-2 group from 39.5662.31 mg/L
to 17.8461.59 mg/L (p#0.001) with no significant differences
between groups. The mean body weights of all animals increased
from 236.77619.34 g to 417.13646.58 g (p#0.001) during the
three months of the study with no significant differences between
groups.
PLLA exhibits highest colonization rates
Empty negative control defects (Group 1) did not show any
relevant regeneration by histology at any time during the
experiment. Instead, a membrane of fibrous connective tissue
formed between the two margins of the bony defect. Positive
control defects implanted with bovine spongiosa (Group 2) showed
a late onset of bone formation, which began slowly after 4 weeks,
linked to degradation of the avital implant trabeculae. Most of the
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bone marrow spaces. Defects implanted with plain PLLA scaffolds
(Group 3) were colonized by large numbers of cells, but showed
only a small amount of bone formation. Ossification mainly took
place in the marginal areas of the defect adjacent to old vital bone.
Defects implanted with PLLA/BMP-2 (Group 4) showed an early
onset of bone regeneration throughout the whole defect site after 4
weeks (Fig. 1a). Formation of bone marrow spaces and continuous
osteointegration at the defect margins could be observed after 8
weeks.
To elucidate whether PLLA nanofiber scaffolds support the
formation of cell settlements in a bone defect, cell counts of HE
stained sections were performed. As shown in figure 2, cell densities
Figure 1. Histological analysis of a defect filled with PLLA/BMP-
2. (a) New bone ossicle with active osteoblasts on the upper right edge
and lining cells on the opposite edge in a defect implanted with PLLA/
BMP-2 after 8 weeks (Hematoxylin-Eosin, BF). (b) New bone formation
in a defect filled with PLLA/BMP-2 after 12 weeks, viewed under visible
light, showing the remains of PLLA nanofibers (Masson-Goldner, BF). (c)
The same micrograph as in ‘b’ under polarized light microscopy,
revealing the full extent of bone incorporation through the nanofiber
scaffold as well as some loose collagen fibers at the top (Masson-
Goldner, POL).
doi:10.1371/journal.pone.0025462.g001
Figure 2. Mean cell densities [n] per implant. Mean cell densities
per implant reached the highest levels in the PLLA group. After 8 weeks
cell densities in PLLA and bovine spongiosa groups were significantly
higher than in the negative control group. After 12 weeks cell densities
in the PLLA group were significantly higher than in negative control and
bovine spongiosa groups. *p,0.05.
doi:10.1371/journal.pone.0025462.g002
Figure 3. Radiological density [HU] of defect areas as measured
by cranial CT-scans. The bovine spongiosa group increased by
around 400 HU over the 12 week period, comparable to that of the
PLLA group. The PLLA/BMP-2 group in contrast increased by more than
850 HU over the same period. There was no longer any statistically
significant difference between bovine spongiosa and PLLA/BMP-2 at
weeks 8 and 12. *p,0.05.
doi:10.1371/journal.pone.0025462.g003
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compared to negative controls. Significance was reached in the
case of PLLA nanofiber scaffolds in comparison to negative control
defects (p#0.001) and positive control defects (p=0.048) after 12
weeks (Fig. 2). Finally, polarized light microscopyprovided evidence
that PLLA and PLLA/BMP-2 nanofibers could be incorporated
into the newly formed bone without the interposition of connective
tissue (Fig. 1b+c). No histological foreign body reaction could be
seen with either PLLA or PLLA/BMP-2 implants.
Bone density gain in PLLA/BMP-2 is higher than in bovine
spongiosa
When bovine spongiosa was implanted into defects, means of
654684 HU were detected after 4 weeks, which was significantly
Figure 4. 3D reconstructions of cranial CT-scans used for quantification of radiological bone density. (a) Negative control, 12 weeks. (b)
Positive control, 12 weeks. (c) PLLA, 12 weeks. (d) PLLA/BMP-2, 12 weeks.
doi:10.1371/journal.pone.0025462.g004
Figure 5. Montages (363) used for histomorphometry generated with the Leica QUIPS package. (a) Negative control, 12 weeks. (b)
Positive control, 12 weeks. (c) PLLA, 12 weeks. (d) PLLA/BMP-2, 12 weeks (Masson-Goldner, BF).
doi:10.1371/journal.pone.0025462.g005
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Within three months, radiological densities increased independent
of treatment as demonstrated in figure 3. It is remarkable that this
increase was approximately two times higher in animals implanted
with PLLA/BMP-2 nanofiber scaffolds compared to the other
treatments (856 HU increase with PLLA/BMP-2 versus 499 HU
increase with PLLA; 409 HU increase with bovine spongiosa and
538 HU increase in untreated defects). This resulted in higher
bone densities as compared to empty defects (p=0.003 after 4
weeks; p=0.003 after 8 weeks and p=0.083 after 12 weeks) as
well as blank PLLA nanofiber scaffolds (p#0.001 after 4 weeks;
p=0.013 after 8 weeks and p=0.008 after 12 weeks). Further-
more, after 12 weeks there was no longer any statistical difference
between the bovine spongiosa group (positive control) and de-
fects treated with PLLA/BMP-2 nanofiber scaffolds (p=0.666).
Figure 4 shows 3D reconstructions of the cranial CT-scans of all
four groups after 12 weeks (Fig. 4).
PLLA/BMP-2 induces early-onset bone formation
The observed increase in radiological bone density was reflected
in the formation of hard callus as determined by histomorphometry
(Fig. 5). After implantation of PLLA/BMP-2 nanofiber scaffolds
approximately 30% of the defect site were filled with hard callus
after 4 weeks as shown in figure 6. Thiswas significantly higher than
that observed in all other treatments (p#0.001). During the course
of the experiment, callus formation in the PLLA/BMP-2 group
increased up to 45% after 12 weeks which was significantly higher
than hard callus formation in the negative control group (p#0.001)
and the PLLA group (p=0.002), but there was no significant
difference between the PLLA/BMP-2 group and the bovine
spongiosa group after 12 weeks (p=0.140) (Fig. 6).
Use in combination with BMP-2 leads to sustained
osteoinduction
Increased hard callus formation in the PLLA/BMP-2 group was
accompanied by a constant increase of osteocalcin-positive cells as
determined by immunostaining (Fig. 7). PLLA/BMP-2 scaffolds
induced significantly higher expression of osteocalcin (p#0.001)
compared to all other implants after 8 and 12 weeks. PLLA
scaffolds showed a tendency towards growth at first, but then
reached values even lower than the negative group (p=0.007)
after 12 weeks (Fig. 8a).
An increasing number of BMP-2 positive cells could also be
observed in the PLLA/BMP-2 group. After 12 weeks the PLLA/
BMP-2 group showed a significantly higher expression of BMP-2
than all other groups (negative control and PLLA p#0.001;
positive control p=0.05). It is remarkable that the expression of
BMP-2 in the PLLA group reached a highly significant maximum
after 8 weeks (p#0.001) before decreasing again towards the end
of the observation period (Fig. 8b).
With regard to the expression of Smad5, a significant
dominance of the positive control group (negative control p#
0.001; PLLA p=0.025 and PLLA/BMP-2 p=0.002) could be
observed after 4 weeks, but this difference had already disappeared
after 8 weeks. Both PLLA and PLLA/BMP-2 groups exhibited
equal numbers of Smad5 positive cells after 8 weeks, higher than
Figure 6. Formation of new bone in relation to the whole
defect area [%] as determined by histomorphometry. Defects
implanted with PLLA/BMP-2 showed significantly faster bone regener-
ation than every other group. After 12 weeks, a significant difference
could no longer be detected between PLLA/BMP-2 and bovine
spongiosa groups, although mean relative bone formation differed by
,20%. *p,0.05.
doi:10.1371/journal.pone.0025462.g006
Figure 7. Immunohistological staining for Osteocalcin. (a) Osteocalcin-positive cells in an ossicle of new bone adjacent to nanofiber scaffold in
a defect implanted with PLLA/BMP-2 after 8 weeks. (b) Negative control for osteocalcin from the center of the same defect (DAB-Hematoxylin, BF).
doi:10.1371/journal.pone.0025462.g007
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expression of Smad5 was significantly higher in the PLLA/BMP-2
group than in all other groups (negative control p=0.003; positive
control p=0.011 and PLLA p#0.001) (Fig. 8c).
Discussion
With regard to the reconstruction of critical size calvarial defects
in the rat, three main options have been described in the literature:
bare bridging with xenogenic [49] or allogenic [50] substances,
implants combined with growth factors [51–53] or gene therapy
using modified MSCs [54,55]. Synthetic xenogenic 3D implants
may have certain different characteristics ranging from different
initial materials to varying 3D structure.
Achieving adequate osteointegration of a scaffold seems to be
more of a challenge than incorporation of growth factors, although
there may be a link between these two properties [56]. As Woo et
al. recently showed, 3D nanofibrous PLLA scaffolds are superior
to solid walled PLLA scaffolds of equal porosity in respect to bone
regeneration in vivo. This effect was traced back to the fact that
nanofiber scaffolds may mimic the fibrous morphology of type I
collagen and therefore of bone ECM [57]. Although nanofiber
scaffolds undergo faster degradation in vitro compared to solid
walled scaffolds, it is not yet clear if this effect also contributes to
their superior properties in vivo [58]. To make use of the positive
effects mentioned above and to facilitate cell migration, PLLA
nanofiber scaffolds were implanted into critical size defects. These
scaffolds were colonized by cells resulting in significantly higher
cell densities as compared to empty defects, indicating that the
nanofiber scaffold forms a stable matrix for filling large bone
defects. This was confirmed by polarized light microscopy
demonstrating a nanofiber fiber network within the defect over a
period of 3 months. However, based on in vitro data obtained by
other researchers [59], it can be assumed that the mechanical
stability of the scaffold decreases over time. In this case, the onset
of new bone formation has to occur early in order to compensate
for this effect. In our study, PLLA nanofibers alone had no impact
on the formation of new bone as demonstrated by histomorphom-
etry, immunostaining or CT scans. These findings correspond well
to earlier in vitro experiments indicating that plain PLLA nanofiber
scaffolds have a positive effect on cell density, but also result in
down-regulation of genes associated with the osteoblast lineage
[31,60]. This delay in osteoblast differentiation can be overcome
by application of BMP-2, which has been evaluated in conjunction
with a number of carrier substances [2–5].
As each carrier has an influence on growth factor delivery,
physicochemical and biological properties of its initial material are
very important. Most carriers loaded with BMP-2 show an early
burst of BMP-2 release with a reduction of retained BMP-2 to less
than 10% within the first 5 days [61].
When incorporated in core shell fibers, the release pattern of
BMP-2 can be modulated by variations in the polymer-ratios
between polycaprolactone and polyethyleneoxide [48]. This release
can be prolonged by direct incorporation of BMP-2 into Poly
(lactide-cp-glycolide)/hydroxylapatite composite nanofibers [47].
When electrospun into nanofibers the incorporated rhBMP-2
retains its structural integrity with respect to size and allotment of
a-helices, b-sheets, helix-turn-helices and b-antiparallel structures,
although stabilization seemed to be necessary in some way
[46,47,62]. Therefore the core shell fibers as well as the PLGA/
HAp nanofibers are able to induce osteoblast differentiation as well
as formation of new bone. Similar results can be obtained when
hMSC are cultured on PLLA/BMP-2 nanofiber scaffolds, which
Figure 8. Mean cell densities [n] of Osteocalcin-, BMP-2- and
Smad5-positive cells as determined by immunohistochemistry.
(a) Mean osteocalcin-positive cells [n] as determined by immunostain-
ing. From 8 weeks onwards, differences between the PLLA/BMP-2
group and all other groups are highly significant. *p,0.05 (b) Mean
BMP-2-positive cells [n] as determined by immunostaining. Expression
of BMP-2 increased with a delay of 4 weeks in the PLLA/BMP-2 group
compared to osteocalcin. After 12 weeks, BMP-2 levels of the PLLA/
BMP-2 group were significantly different from all other groups. *p,0.05
(c) Mean Smad5-positive cells [n] as determined by immunostaining.
Similar to the expression of BMP-2, the expression of Smad5 reached its
maximum after 12 weeks in the PLLA/BMP-2 group. *p,0.05.
doi:10.1371/journal.pone.0025462.g008
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collagen as well as alkaline phosphatase in vitro [41].
When implanted into a critical size defect, a significant increase
of hard callus formation could be observed as early as 4 weeks,
accompanied by an increase in bone density as determined by CT
scans. Taken together with the rapid increase in osteocalcin-
positive cells after 8 weeks and subsequent up-regulation of BMP-2
and Smad5 after 12 weeks, these results indicate that the
incorporated rhBMP-2 should be considered bioactive within the
PLLA nanofiber scaffolds in vivo. Therefore the actual in vivo data,
together with our in vitro data published previously, demonstrate
that PLLA nanofibers can be successfully modified by direct
incorporation of BMP-2. Implant degradation of PLLA nanofibers
did not seem to affect the formation of new bone in the PLLA/
BMP-2 group. Moreover, the fibers were incorporated into the
newly-formed bone. Therefore the assumed degradation of the
PLLA nanofibers and the resulting decrease in mechanical stability
(Paletta et al. 2010) will be compensated by formation of new
bone. However in this study a non-weight-bearing model was
used. With respect to weight bearing bones, the initial stability of
nanofiber scaffolds alone is not sufficient. Here, additional fixation
seems to be necessary until the new bone bridges the defect and
fibers are incorporated into the bone. It is our opinion that this
incorporation screens the material from the immunological
system. This is supported by the finding that no signs of
immunologic reaction were observed, either histologically or by
blood analysis.
These findings lead to the assumption that PLLA/BMP-2
nanofiber scaffolds can overcome these adverse effects either
because BMP-2 is incorporated bioactively and preserved on the
surface throughout the whole observation period, or because of the
low total amount of PLLA due to the scaffold’s high porosity.
Some other experimental models also make use of BMP-2 as a
growth factor as it is well known to promote bone healing. Similar
results on the efficacy of BMP-2 were observed in a study by Patel
et al. comparing different types of rhBMP-2-carrying implants
[51], as well as Patterson et al., who tested hyaluronic acid
hydrogels carrying BMP-2 [49] and Young et al., who used a
similar system [63]. To achieve sufficient osteogenesis or defect
closure however, relatively high concentrations of BMP-2 were
needed in either defect-based [49,64,65] or ectopic models [61].
Electrospun nanofibers loaded with rhBMP-2 represent a viable
alternative here because of their 3D ECM-like structure, their high
physical porosity and their ability to incorporate a bioactive
growth factor which may help to reduce the concentration of such
factors required.
Conclusion
The aims of this study were to evaluate the influence of three-
dimensional PLLA nanofiber scaffolds on bone formation in vivo
and to analyze whether incorporated BMP-2 could enhance their
efficacy. PLLA nanofiber scaffolds were shown to facilitate cell
immigration and thus to achieve high cell densities. However they
lacked adequate osteogenic stimuli to allow further differentiation
of those cells. The incorporation of rhBMP-2 into PLLA
nanofibers could overcome this problem. Hence PLLA/BMP-2
implants were able to close critical size calvarial defects within 8
weeks. Increased expression of osteocalcin, BMP-2 and Smad5
suggests a subsequent activation of the osteoblast lineage.
Therefore PLLA/BMP-2 nanofiber scaffolds combine a suitable
matrix for cell migration with an osteoinductive stimulus.
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